Quick Reference Guide:
News Releases
November 14, 2011 - Anavex Successfully Completes A Phase 1 Clinical Trial For ANAVEX 2-73
October 12, 2011 - Anavex Appoints Dr. George Tidmarsh As Executive Director
September 15, 2011 - Anavex to Present Data on ANAVEX 2-73, Lead Compound for Alzheimer’s Disease, at Japan Neuroscience Society Special Symposium
July 26, 2011 - Anavex Presents Data on Neuroprotective Evidence for ANAVEX 2-73, Lead Compound for Alzheimer’s Disease
July 25, 2011 - Anavex Presents Data on Potential Dual Utility of ANAVEX 2-73 in Both Amyloid and Tau Pathology
July 15, 2011 - Anavex to Present at Alzheimer’s Association International Conference on Alzheimer’s Disease
July 11, 2011 - Anavex Raises $1.575 Million
July 06, 2011 - Anavex Rapidly Advances ANAVEX 2-73 for Alzheimer’s Disease, Phase I Clinical Trial Progressing Well
June 08, 2011 - Anavex Advances Second Lead Compound; Initiates Scale-up Manufacturing of ANAVEX 1-41
May 23, 2011 - ANAVEX 2-73 Advances Phase I Clinical Trial for Alzheimer’s Disease
May 17, 2011 - Anavex Comments on New Alzheimer’s Disease Diagnostic Guidelines
May 13, 2011 - Anavex Appoints Robert Chisholm to Board of Directors
April 20, 2011 - Anavex: First-In-Human Dosing Commenced in Anavex 2-73 Clinical Trial for Alzheimer’s Disease
April 08, 2011 - Anavex Appoints Dr. Christopher Shackleton as an Advisor
April 06, 2011 - Anavex to Hold Annual Meeting on April 11, 2011
March 31, 2011 - Anavex Screening Healthy Volunteers for Phase I, First-In-Human Clinical Study in Alzheimer’s Disease
March 15, 2011 - Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease
March 01, 2011 - Anavex Appoints Dr. Jeffrey Cummings to its Scientific Advisory Board
February 23, 2011 - Anavex Appoints Dr. Rachelle Doody to Scientific Advisory Board
February 16, 2011 - Anavex Adds Dr. Paul Aisen to Scientific Advisory Board
February 04, 2011 - Anavex Strengthens Management Team with Addition of VP, Clinical Development & Medical Affairs
January 18, 2011 - Anavex Comments on President Obama’s Signing of National Alzheimer’s Project Act into Law
January 06, 2011 - Alzheimer’s Weekly names ANAVEX 2-73 the number one most promising trial drug in Alzheimer’s disease and Anavex’s Phase I clinical program as “Trial of the Year”
December 21, 2010 - Anavex Files Phase I Regulatory Submission for ANAVEX 2-73 in Alzheimer’s Disease
September 13, 2010 - ANAVEX 2-73: Journal of Psychopharmacology Publishes Anti-Amnesic and Neuroprotective Data Against Amyloid Toxicity for First of a New Class in Alzheimer’s Disease
September 08, 2010 - Anavex to Present at Rodman & Renshaw Healthcare Conference September 13 in New York City
August 10, 2010 - Anavex Appoints Contract Research Organizations to Initiate Phase I/IIa Clinical Programs, Regulatory Strategies in Alzheimer’s Disease
June 07, 2010 - Anavex Relocates Executive Management Office to New Jersey
May 04, 2010 - Anavex Reports Animal Study Results as Lead Alzheimer’s Compound Approaches Phase 1 Clinical Trials
March 03, 2010 - Anavex Comments on Failure of Pfizer and Medivation’s Alzheimer’s Investigational Drug Dimebon During Phase 3 Clinical Trials
January 19, 2010 - ANAVEX Appoints Dr. Cameron Durrant Executive Chairman of the Board
September 30, 2009 - ANAVEX Contracts FORENAP Pharma for Clinical Trials of ANAVEX 2-73 in Alzheimer's Disease
September 21, 2009 - Anavex Completes Scale-Up Manufacturing of ANAVEX 2-73 for Phase 1 Alzheimer's Disease Clinical Trials
August 27, 2009 - Anavex Reports Sigma Receptor Review Published in Leading Journal
August 11, 2009 - Anavex Announces Private Placement
April 09, 2009 - Anavex Receives $2.14 Million Capital Injection
April 08, 2009 - Pharmawire: Medivation, Anavex May Lower Oxidative Stress
February 10, 2009 - Anavex Appoints Leading Alzheimer’s Disease Expert Dr. Mark Smith to Scientific Advisory Board
January 30, 2009 - Anavex Scales Up Synthesis of ANAVEX 2-73 for Phase 1 Alzheimer’s Disease Study
December 17, 2008 - Ground-breaking Anti-amnesic and Neuroprotective Effects of Alzheimer's Compound Anavex 1-41 Published in Journal of Neuropsychopharmacology
December 04, 2008 - Anavex Presents Potent Neuroprotective Effects of Anavex 1-41 at Neuroscience 2008
September 02, 2008 - Anavex Completes Successful Preclinical Studies on Lead Alzheimer’s Drug Candidate
July 30, 2008 - Anavex Presents Neuroprotective Effects of Anavex 1-41 at the International Conference on Alzheimer’s Disease 2008
June 24, 2008 - Anavex Life Sciences Corp. will Present New Findings at the International Conference on Alzheimer’s Disease 2008 (July 26-31, 2008, Chicago, USA)
June 03, 2008 - Anavex Further Strengthens Board of Directors
May 20, 2008 - Anavex Announces Appointment of Oncology Specialist to Board of Directors, Changes to Executive Management
April 16, 2008 - Dr. Dimitri Goundis to Assist in Drug Development for Anavex
March 10, 2008 - Anavex 7-1037 Reduces Rate of Cancer Tumor Growth 69% in Pre-Clinical Studies, Compared to Currently Marketed Drug Dacarbazine Showing No Measurable Activity
January 22, 2008 - Anavex Outlines Corporate Milestones, Drug Advancement Plans for 2008
December 17, 2007 - Anavex Strengthens Board of Directors
December 06, 2007 - Anavex Advances Drug Candidates for Treatment of Epilepsy
November 28, 2007 - Anavex Advances Drug Candidate for Treatment of Alzheimer’s Disease
November 02, 2007 - Anavex Life Sciences Engages Primoris Group to Provide Investor Relations Services
Copyright © 2001-2012 Primoris Group Inc.
Home | Services | News Releases | Media | Testimonials | Links | Contact Us